

Study Number: C12011-01
Test Type: TOX
Route: Oral Gavage
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Bumetrizole
CAS Number: 3896-11-5

Date Report Requested: 05/20/2021
Time Report Requested: 14:46:49
Lab: Battelle

Study Number: C12011-01
Study Sex: Male
PWG Approval Date: See web page for date of PWG Approval
Version: v1.2.0

Study Number: C12011-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Bumetrizole

CAS Number: 3896-11-5

Date Report Requested: 05/20/2021

Time Report Requested: 14:46:49

Lab: Battelle

Male						
	Phase Day	Treatment Groups (mg/kg)				
		0	30	100	300	1000
Urea Nitrogen (mg/dL)	SD 14	17.2 ± 0.5 (5)	17.4 ± 0.5 (5)	16.2 ± 0.8 (5)	15.8 ± 1.1 (4)	16.0 ± 0.3 (5)
Percent of Control			101.2	94.2	91.6	93.0
Creatinine (mg/dL)	SD 14	0.42 ± 0.02 (5)	0.38 ± 0.02 (5)	0.42 ± 0.02 (5)	0.40 ± 0.00 (4)	0.42 ± 0.02 (5)
Percent of Control			90.5	100.0	95.2	100.0
Glucose (mg/dL)	SD 14	172.0 ± 9.4 (5)	187.2 ± 19.1 (5)	166.4 ± 12.9 (5)	189.0 ± 22.0 (4)	158.4 ± 13.7 (5)
Percent of Control			108.8	96.7	109.9	92.1
Total Protein (g/dL)	SD 14	6.64 ± 0.11 (5)	6.76 ± 0.10 (5)	6.66 ± 0.09 (5)	6.68 ± 0.11 (4)	6.72 ± 0.06 (5)
Percent of Control			101.8	100.3	100.5	101.2
Globulin (g/dL)	SD 14	2.22 ± 0.10 (5)	2.28 ± 0.08 (5)	2.34 ± 0.07 (5)	2.30 ± 0.11 (4)	2.34 ± 0.07 (5)
Percent of Control			102.7	105.4	103.6	105.4
A/G Ratio	SD 14	2.01 ± 0.12 (5)	1.97 ± 0.07 (5)	1.85 ± 0.07 (5)	1.91 ± 0.09 (4)	1.88 ± 0.06 (5)
Percent of Control			98.1	92.1	95.2	93.4
Albumin (g/dL)	SD 14	4.42 ± 0.10 (5)	4.48 ± 0.02 (5)	4.32 ± 0.07 (5)	4.38 ± 0.05 (4)	4.38 ± 0.04 (5)
Percent of Control			101.4	97.7	99.0	99.1
Cholesterol (mg/dL)	SD 14	116.2 ± 7.6 (5)	125.8 ± 5.1 (5)	128.0 ± 4.1 (5)	117.0 ± 3.5 (4)	123.0 ± 2.9 (5)
Percent of Control			108.3	110.2	100.7	105.9
Triglyceride (mg/dL)	SD 14	98.2 ± 8.9 (5)	78.0 ± 2.0 (5)	109.4 ± 11.5 (5)	72.0 ± 11.1 (4)	80.6 ± 4.8 (5)
Percent of Control			79.4	111.4	73.3	82.1
Alanine Aminotransferase (IU/L)	SD 14	51.6 ± 2.8 (5)	57.0 ± 2.4 (5)	52.4 ± 1.8 (5)	56.5 ± 4.4 (4)	51.4 ± 1.7 (5)
Percent of Control			110.5	101.6	109.5	99.6
Alkaline Phosphatase (IU/L)	SD 14	194.4 ± 4.4 (5)	207.8 ± 15.7 (5)	202.0 ± 9.4 (5)	200.0 ± 4.5 (4)	195.4 ± 11.9 (5)
Percent of Control			106.9	103.9	102.9	100.5

Study Number: C12011-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Bumetrizole

CAS Number: 3896-11-5

Date Report Requested: 05/20/2021

Time Report Requested: 14:46:49

Lab: Battelle

Male

		Treatment Groups (mg/kg)									
Phase Day		0		30		100		300		1000	
Creatine Kinase (IU/L)	SD 14	189.5	± 29.0 (4)	171.4	± 31.2 (5)	135.4	± 7.5 (5)	197.0	± 41.2 (4)	173.6	± 21.4 (5)
Percent of Control				90.4		71.5		104.0		91.6	
Sorbitol Dehydrogenase (IU/L)	SD 14	10.3	± 1.4 (5) *	12.0	± 0.9 (5)	11.1	± 0.8 (5)	14.2	± 2.6 (4)	13.1	± 1.0 (5)
Percent of Control				115.9		107.4		137.4		127.3	
Bile salt/acids (umol/L)	SD 14	22.8	± 3.9 (5)	13.6	± 2.1 (5)	13.8	± 2.6 (5)	14.8	± 5.3 (4)	13.2	± 3.0 (5)
Percent of Control				59.6		60.5		64.7		57.9	

Study Number: C12011-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Bumetrizole

CAS Number: 3896-11-5

Date Report Requested: 05/20/2021

Time Report Requested: 14:46:49

Lab: Battelle

LEGEND

Values given as mean $\pm$ SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100

SD – Study Day

Statistical analysis were performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

One value for Creatine Kinase in the 0 mg/kg group was excluded because it was an outlier.

**** END OF REPORT ****